Mediterranean Diet and Physical Activity in Breast Cancer Patients Under Hormone Therapy
Impact of a Mediterranean-type Diet and Promotion of Physical Activity on Nutritional Status and Cardiometabolic Risk in Breast Cancer Patients Undergoing Adjuvant Hormone Therapy
1 other identifier
interventional
150
1 country
1
Brief Summary
This study aims to evaluate body weight status, lifestyle patterns, and cardiometabolic risk in women in remission from breast cancer undergoing adjuvant hormone therapy, and to assess the effects of a structured nutritional intervention based on the Mediterranean diet combined with physical activity promotion. A total of 150 women treated with adjuvant hormone therapy are recruited from the oncology department of Akid Othmane Hospital in Oran, Algeria. Participants include women receiving tamoxifen or aromatase inhibitors. Baseline assessments include anthropometric measurements (body weight, body mass index, waist and hip circumferences), socioeconomic characteristics, and lifestyle evaluation. Dietary intake is assessed using 24-hour dietary recalls and 3-day food records. Total energy intake, macronutrient and micronutrient composition, dietary habits, meal distribution, and adherence to the Mediterranean diet (MEDAS score) are evaluated. Physical activity level, sedentary behavior, daily energy expenditure, and energy balance are also determined. Cardiometabolic risk is assessed through measurement of blood pressure, fasting blood glucose, lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides), uric acid, albumin, creatinine, urea, and calculation of atherogenic ratios. A structured educational program promoting adherence to the Mediterranean diet and increased physical activity is implemented. Anthropometric, dietary, lifestyle, and cardiometabolic parameters are monitored over time to evaluate changes associated with the intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable cardiovascular-diseases
Started May 2022
Typical duration for not_applicable cardiovascular-diseases
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 2, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 26, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 24, 2025
CompletedFirst Submitted
Initial submission to the registry
February 17, 2026
CompletedFirst Posted
Study publicly available on registry
March 2, 2026
CompletedMarch 2, 2026
February 1, 2026
2.8 years
February 17, 2026
February 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in waist circumference
Change in waist circumference measured in centimeters between baseline and after 3 months of lifestyle intervention.
Baseline and 3 months
Secondary Outcomes (3)
Change in body mass index (BMI)
Time Frame: Baseline and 3 months
Change in lipid profile
Baseline and 3 months
Change in systolic and diastolic blood pressure
Baseline and 3 months
Study Arms (1)
Lifestyle intervention group
OTHERBreast cancer patients receiving a Mediterranean diet intervention combined with physical activity promotion for 3 months, with assessments conducted at baseline and after the intervention.
Interventions
Dietary counseling and guidance to promote adherence to the Mediterranean diet over a 3-month period.
Counseling and structured recommendations to increase regular physical activity over a 3-month period.
Eligibility Criteria
You may qualify if:
- Histologically confirmed hormone receptor-positive breast cancer
- Breast cancer survivors receiving adjuvant endocrine therapy (tamoxifen or aromatase inhibitors) for ≥3 months
- No recurrence or second primary malignancy
- Ability to perform moderate-intensity physical activity
- Consecutively recruited during routine surveillance visits
You may not qualify if:
- Incomplete or discontinued hormone therapy
- Concurrent ovarian suppression
- Use of lipid-lowering medications
- Severe uncontrolled comorbidities (e.g., diabetes, cardiac, or hepatic disease)
- Cognitive or physical impairments preventing informed consent or participation
- Restrictive dietary regimens
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- MOHAMEDI Ilhem Sarra Manellead
- University of Oran 1collaborator
Study Sites (1)
Akid Othmane Hospital
Oran, Aïn-El-Turck, 31300, Algeria
Related Publications (1)
Mohamedi ISM, Ghomari-Boukhatem H, Moussaoui I, Raiah M, Bouchenak M. Lifestyle factors and cardiometabolic risk in breast cancer patients under different hormones therapy. Med J Nutrition Metab. 2025; 18(3):194-203. doi:10.1177/1973798X251353349.
BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 17, 2026
First Posted
March 2, 2026
Study Start
May 2, 2022
Primary Completion
February 26, 2025
Study Completion
June 24, 2025
Last Updated
March 2, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared. Only aggregated results, such as means and standard deviations of measured outcomes, will be published to evaluate the impact of the Mediterranean diet and physical activity promotion. All data will remain confidential and no personal identifiers will be made publicly available